Experimental ‘Inside-the-Body’ cancer therapy shows remarkable early results in blood cancer trial

NEW JERSEY: An experimental cancer treatment that creates disease-fighting immune cells directly inside a patient's body has shown promising early results in people with advanced blood cancer, raising hopes for a simpler and more accessible alternative to traditional CAR-T therapy.

The treatment, known as LB2501, is being developed by biotechnology company Legend Biotech and is currently being tested in patients with relapsed or treatment-resistant B-cell non-Hodgkin lymphoma, a type of blood cancer that affects white blood cells involved in the immune system.

Early findings from an ongoing Phase 1 clinical trial showed encouraging responses among patients who had few remaining treatment options.

What makes this treatment different?

Traditional CAR-T therapy is one of the most advanced forms of cancer immunotherapy available today. It works by collecting a patient's immune cells, genetically modifying them in a laboratory to recognize cancer, and then infusing them back into the patient.

While highly effective for some cancers, the process is complex, expensive, and time-consuming. It often requires specialized manufacturing facilities and can take weeks before treatment is ready.

LB2501 aims to eliminate much of that complexity.

Instead of removing and engineering immune cells outside the body, the experimental therapy is designed to instruct the patient's own immune system to create cancer-fighting CAR-T cells internally through a single intravenous infusion. If successful, this approach could dramatically simplify treatment delivery and potentially make CAR-T therapy available to more patients worldwide.

What did the study find?

As of April 2026, researchers had treated 12 patients with relapsed or refractory B-cell non-Hodgkin lymphoma across two dosing groups.

The most encouraging results were observed in the higher-dose group. All six patients responded to treatment, and five achieved a complete response, meaning no detectable signs of cancer remained following therapy.

Researchers cautioned that these are preliminary findings from a small number of patients and that longer follow-up is needed to determine how durable the responses will be.

Nevertheless, cancer specialists described the results as an important milestone in the rapidly evolving field of in vivo CAR-T therapy, which seeks to generate cancer-fighting cells directly within the body rather than in a laboratory.

Safety profile appears encouraging

According to the company, no dose-limiting toxicities, serious adverse events, or treatment-related deaths were reported during the study period.

Some patients experienced infusion-related reactions, but these were generally manageable and resolved within a median of two days. Researchers also reported no severe neurological complications, which are among the safety concerns sometimes associated with conventional CAR-T therapies.

Why experts are paying attention

Scientists have spent years trying to develop "off-the-shelf" CAR-T approaches that can reduce manufacturing complexity and improve patient access.

Experts say one of the major advantages of an in vivo approach could be its ability to avoid lengthy laboratory manufacturing processes while potentially lowering costs and expanding availability beyond specialized treatment centers.

The development comes amid growing investment in next-generation CAR-T technologies, with several major pharmaceutical companies increasing their focus on therapies capable of generating cancer-fighting immune cells directly inside patients.

Important limitations remain

Despite the excitement, researchers emphasize that LB2501 remains an experimental therapy.

The trial is still in its earliest stages, involving only 12 patients, and larger studies will be required to confirm both safety and effectiveness before the treatment can be considered for regulatory approval or routine clinical use.

Additional clinical data from the study are expected to be presented at the European Hematology Association Congress later this month, where researchers will provide a more detailed analysis of patient outcomes and treatment performance.

If future studies confirm these early findings, experts believe the technology could represent a significant step toward making advanced cell-based cancer therapies more practical, scalable, and accessible for patients around the world.

---

Stay informed, stay alert

CLICK HERE TO JOIN Medical News Pakistan on WhatsApp for real-time health alerts, expert insights, and breakthrough medical discoveries.